Antonella d'Arminio-Monforte

Summary

Affiliation: University of Milan
Country: Italy

Publications

  1. ncbi request reprint Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting
    Antonella d'Arminio Monforte
    Department of Health Sciences, Institute of Infectious Diseases, University of Milan, Milan, Italy
    Antivir Ther 19:319-24. 2014
  2. pmc Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patients
    Lidia Gazzola
    Department of Health Sciences, Clinic of Infectious Diseases, San Paolo Hospital, University of Milan, Via A, Di Rudinì, 8, Milan 20142, Italy
    J Transl Med 11:51. 2013
  3. doi request reprint What do we know about antiretroviral treatment of HIV in women?
    Antonella D arminio Monforte
    San Paolo University Hospital, Milan, Italy
    Antivir Ther 18:27-34. 2013
  4. pmc Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis
    Enrico Girardi
    Department of Epidemiology and Preclinical Research, National Institute for Infectious Diseases L, Spallanzani, IRCCS, Via Portuense 292, 00149, Rome, Italy
    BMC Health Serv Res 12:38. 2012
  5. pmc Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI
    Carlo Torti
    University of Brescia, Italy
    BMC Infect Dis 11:23. 2011
  6. ncbi request reprint Predictive role of the three-month CD4 cell count in the long-term clinical outcome of the first HAART regimen
    A d' Arminio Monforte
    Institute of Infectious and Tropical Diseases, University of Milan, L Sacco Hospital, Italy
    Biomed Pharmacother 55:16-22. 2001
  7. pmc HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies
    Antonella D arminio Monforte
    Dipartimento di Medicina, Chirurgia e Odontoiatria, Clinica di Malattie Infettive e Tropicali, Azienda Ospedaliera Polo Universitario San Paolo, via A Di Rudinì 8 20142 Milano, Italy
    AIDS 22:2143-53. 2008
  8. doi request reprint Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis
    Antonella d'Arminio Monforte
    Clinic of Infectious and Tropical Diseases, Dept of Medicine, Surgery and Dentistry, San Paolo Hospital, University of Milan, via A Di Rudinì 8 20142, Milan, Italy
    Clin Infect Dis 49:612-22. 2009
  9. doi request reprint Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcome
    Antonella d'Arminio Monforte
    Clinic of Infectious and Tropical Diseases, Department of Medicine, Surgery and Dentistry, S Paolo Hospital, University of Milan, Milan, Italy
    Antivir Ther 16:1103-12. 2011
  10. ncbi request reprint Cerebrovascular disease in highly active antiretroviral therapy-treated individuals: incidence and risk factors
    Antonella D arminio Monforte
    Institute of Infectious Diseases and Tropical Medicine, University of Milan, Milan, Italy
    J Neurovirol 11:34-7. 2005

Detail Information

Publications34

  1. ncbi request reprint Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting
    Antonella d'Arminio Monforte
    Department of Health Sciences, Institute of Infectious Diseases, University of Milan, Milan, Italy
    Antivir Ther 19:319-24. 2014
    ..The main objective is to evaluate the efficacy and durability of lopinavir-ritonavir monotherapy (LPV/r-MT) in virologically controlled HIV-positive individuals switching from combination antiretroviral therapy (cART)...
  2. pmc Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patients
    Lidia Gazzola
    Department of Health Sciences, Clinic of Infectious Diseases, San Paolo Hospital, University of Milan, Via A, Di Rudinì, 8, Milan 20142, Italy
    J Transl Med 11:51. 2013
    ..HIV-infected patients display an increased and early incidence of osteopenia/osteoporosis. We investigated whether bone metabolism disorders in HIV-infected patients are related to immune hyperactivation and premature immune senescence...
  3. doi request reprint What do we know about antiretroviral treatment of HIV in women?
    Antonella D arminio Monforte
    San Paolo University Hospital, Milan, Italy
    Antivir Ther 18:27-34. 2013
    ..Understanding these factors, in conjunction with an increase in clinical trial and real-world data specific to women with HIV is required to provide clearer guidance on optimum ART options for women...
  4. pmc Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis
    Enrico Girardi
    Department of Epidemiology and Preclinical Research, National Institute for Infectious Diseases L, Spallanzani, IRCCS, Via Portuense 292, 00149, Rome, Italy
    BMC Health Serv Res 12:38. 2012
    ..Identification of the determinants of access to investigational drugs is important to promote equity and scientific validity in clinical research. We aimed to analyze factors associated with the use of experimental antiretrovirals in Italy...
  5. pmc Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI
    Carlo Torti
    University of Brescia, Italy
    BMC Infect Dis 11:23. 2011
    ..Data regarding CD4+ recovery after switching from protease inhibitor (PI)-based regimens to regimens not containing PI are scarce...
  6. ncbi request reprint Predictive role of the three-month CD4 cell count in the long-term clinical outcome of the first HAART regimen
    A d' Arminio Monforte
    Institute of Infectious and Tropical Diseases, University of Milan, L Sacco Hospital, Italy
    Biomed Pharmacother 55:16-22. 2001
    ..93; 95% Cl: 1.16--7.38). The three-month immunologic response is a reliable predictor of long-term clinical outcome...
  7. pmc HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies
    Antonella D arminio Monforte
    Dipartimento di Medicina, Chirurgia e Odontoiatria, Clinica di Malattie Infettive e Tropicali, Azienda Ospedaliera Polo Universitario San Paolo, via A Di Rudinì 8 20142 Milano, Italy
    AIDS 22:2143-53. 2008
    ..To evaluate deaths from AIDS-defining malignancies (ADM) and non-AIDS-defining malignancies (nADM) in the D:A:D Study and to investigate the relationship between these deaths and immunodeficiency...
  8. doi request reprint Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis
    Antonella d'Arminio Monforte
    Clinic of Infectious and Tropical Diseases, Dept of Medicine, Surgery and Dentistry, San Paolo Hospital, University of Milan, via A Di Rudinì 8 20142, Milan, Italy
    Clin Infect Dis 49:612-22. 2009
    ..We evaluated the correlation between the occurrence of different AIDS-defining illnesses (ADIs) and chronic HCV infection or HCV-related liver cirrhosis in a large Italian cohort of human immunodeficiency virus (HIV)-infected subjects...
  9. doi request reprint Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcome
    Antonella d'Arminio Monforte
    Clinic of Infectious and Tropical Diseases, Department of Medicine, Surgery and Dentistry, S Paolo Hospital, University of Milan, Milan, Italy
    Antivir Ther 16:1103-12. 2011
    ..To study the prevalence, predictors and outcome of late HIV diagnosis in the Icona cohort, according to the new European consensus definition of late diagnosis...
  10. ncbi request reprint Cerebrovascular disease in highly active antiretroviral therapy-treated individuals: incidence and risk factors
    Antonella D arminio Monforte
    Institute of Infectious Diseases and Tropical Medicine, University of Milan, Milan, Italy
    J Neurovirol 11:34-7. 2005
    ..Large-scale epidemiological studies are needed to better define the incidence of cerebrovascular events in HIV-infected patients and the factors associated with their occurrence...
  11. ncbi request reprint Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the Italian Cohort of Antiretroviral-Naive Patients
    Antonella d'Arminio Monforte
    Istituto di Malattie Infettive e Tropicali, Universita di Milano, Milano, Italy
    J Acquir Immune Defic Syndr 38:407-16. 2005
    ....
  12. ncbi request reprint Changing incidence of central nervous system diseases in the EuroSIDA cohort
    Antonella d'Arminio Monforte
    Institute of Infectious and Tropical Diseases, University of Milan, I Sacco Hospital, Via GB Grassi 74, 20157 Milan, Italy
    Ann Neurol 55:320-8. 2004
    ....
  13. ncbi request reprint Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes
    Elisabetta Chiesa
    Institute of Infectious Diseases and Tropical Medicine, University of Milan, Italy
    Antivir Ther 8:27-35. 2003
    ....
  14. ncbi request reprint Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: a retrospective cohort study
    Marco Bongiovanni
    Institute of Infectious and Tropical Diseases, University of Milan, Luigi Sacco Hospital, Via GB Grassi 74, 20157 Milan, Italy
    J Antimicrob Chemother 51:171-4. 2003
    ..Undetectable plasma viraemia was obtained only in patients with < or =5 mutations (61.9%)...
  15. ncbi request reprint Pathological findings in the central nervous system of AIDS patients on assumed antiretroviral therapeutic regimens: retrospective study of 1597 autopsies
    Luca Vago
    Pathology Unit, Department of Clinical Sciences L Sacco, University of Milan, Italy
    AIDS 16:1925-8. 2002
    ....
  16. ncbi request reprint Significant link between sCD30 changes and HIV viremia in patients treated with HAART
    Priscilla Biswas
    Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    J Med Virol 78:1513-9. 2006
    ..The change in sCD30 levels from pre-therapy to the date of first viral suppression could be used to identify patients who are more likely to experience later virological rebound among those who achieve initially virological success...
  17. ncbi request reprint Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects
    Marco Bongiovanni
    Institute of Infectious Diseases and Tropical Medicine, Luigi Sacco Hospital, University of Milan, Via G B Grassi 74, 20157 Milano, Italy
    Antiviral Res 62:53-6. 2004
    ..40 higher risk of discontinuation in the latter group. In our clinical setting IDV/r showed to be less effective and more toxic than LPV/RTV as first-line HAART...
  18. ncbi request reprint Hepatitis B vaccination in HIV-infected subjects
    Marco Bongiovanni
    Clinic of Infectious Diseases, San Paolo Hospital, University of Milan, Milan, Italy
    Curr Mol Pharmacol 1:191-4. 2008
    ..The immunization of all young and middle-aged adults appears to be the most useful strategy to protect all patient-populations at high risk of sexually transmitted diseases...
  19. ncbi request reprint Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals
    Marco Bongiovanni
    Institute of Infectious and Tropical Diseases, Ospedale Luigi Sacco, University of Milan, Via G B Grassi 74, 20157 Milan, Italy
    Int J Antimicrob Agents 26:88-91. 2005
    ..Diarrhoea was the most frequent adverse event leading to discontinuation. HCV-HIV co-infected patients and patients with a short exposure to LPV/r have a higher risk of discontinuing LPV/r and should be strictly monitored...
  20. ncbi request reprint Avascular necrosis of the femoral head in a HIV-1 infected patient receiving lopinavir/ritonavir
    Marco Bongiovanni
    Institute of Infectious Diseases and Tropical Medicine, Luigi Sacco Hospital, University of Milan, Via G B Grassi 74, 20157 Milan, Italy
    Int J Antimicrob Agents 22:630-1. 2003
    ..We report here a case of AVN of the bone in a patient taking the new PI lopinavir (LPV)/ritonavir (RTV) as part of a HAART regimen...
  21. ncbi request reprint Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations
    Marco Bongiovanni
    Institute of Infectious Diseases and Tropical Medicine, University of Milan, Italy
    Antivir Ther 8:209-14. 2003
    ..0% and each extra mutation by 14.5%...
  22. ncbi request reprint Non-invasive markers of liver fibrosis in HCV mono-infected and in HIV/HCV co-infected subjects
    Marco Bongiovanni
    Clinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital, University of Milan, Via di Rudini 8, 20142 Milano, Italy
    Med Chem 4:513-19. 2008
    ..More recently, fibrosis scores calculated from statistical models have been described. This review describes the role of non-invasive markers in assessing hepatic fibrosis in both HCV mono-infected and HIV/HCV co-infected subjects...
  23. ncbi request reprint Cutaneous B-cells non-Hodgkin's lymphoma in a HIV-infected female
    Marco Bongiovanni
    Institute of Infectious Diseases and Tropical Medicine, University of Milan, Italy
    Scand J Infect Dis 37:78-80. 2005
  24. ncbi request reprint Steatohepatitis in HIV-infected subjects: pathogenesis, clinical impact and implications in clinical management
    Marco Bongiovanni
    Clinic of Infectious and Tropical Diseases, San Paolo Hospital, University of Milan, Italy
    Curr HIV Res 5:490-8. 2007
    ..Other studies are mandatory to better elucidate the pathogenesis of NAFLD and the optimal therapeutic strategy for the underlying conditions...
  25. ncbi request reprint Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir
    Marco Bongiovanni
    Institute of Infectious Diseases and Tropical Medicine, Luigi Sacco Hospital, University of Milan, Via G B Grassi 74, 20157 Milan, Italy
    AIDS Res Hum Retroviruses 22:132-8. 2006
    ..01 for both), respectively. Patients with high triglyceride and non- HDL cholesterol levels at the start of LPV/r treatment are at higher risk of developing hyperlipidemia...
  26. ncbi request reprint Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART
    Marco Bongiovanni
    Institute of Infectious and Tropical Diseases, Ospedale Luigi Sacco, University of Milan, Via G B Grassi 74, 20157 Milano, Italy
    J Antimicrob Chemother 55:1003-7. 2005
    ..The long-term virological efficacy of lopinavir/ritonavir-containing highly active antiretroviral therapy (HAART) in HIV-infected patients failing a first-line protease inhibitor (PI)-based regimen is still unclear...
  27. ncbi request reprint Treatment interruptions in HIV-infected subjects
    Marco Bongiovanni
    Clinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital, University of Milan, Italy
    J Antimicrob Chemother 58:502-5. 2006
    ..A clear benefit of STI in patients with chronic infection remains controversial and these benefits are more often observed in patients starting treatment during primary HIV infection...
  28. ncbi request reprint Bone diseases associated with human immunodeficiency virus infection: pathogenesis, risk factors and clinical management
    Marco Bongiovanni
    Clinic of Infectious and Tropical Diseases, Department of Medicine, Surgery and Dentistry, S Paolo Hospital, University of Milan, Italy
    Curr Mol Med 6:395-400. 2006
    ..The administration of bisphosphonates (e.g., alendronate), with calcium and vitamin D supplementation, may be a reasonable and effective option to treat osteoporosis in these subjects...
  29. ncbi request reprint Tenofovir plus didanosine as Nrti backbone in HIV-infected subjects
    Marco Bongiovanni
    Clinic of Infectious Diseases, S Paolo Hospital, University of Milan, Via di Rudini 8, 20142 Milan, Italy
    Curr Med Chem 13:2789-93. 2006
    ....
  30. ncbi request reprint Long-term immunologic outcome in HAART-experienced subjects receiving lopinavir/ritonavir
    Marco Bongiovanni
    Clinic of Infectious Diseases, San Paolo Hospital, University of Milan, Milan, Italy
    AIDS Res Hum Retroviruses 22:1096-105. 2006
    ..The use of LPV/r-based regimens also provided a durable immunologic recovery in highly pretreated HIV-infected subjects...
  31. ncbi request reprint Is the CD4 cell percentage a better marker of immunosuppression than the absolute CD4 cell count in HIV-infected patients with cirrhosis?
    Marco Bongiovanni
    Clinic of Infectious Diseases, San Paolo Hospital, University of Milan, Milan, Italy
    Clin Infect Dis 45:650-3. 2007
    ....
  32. ncbi request reprint Subclinical hypothyroidism in HIV-infected subjects
    Marco Bongiovanni
    Clinic of Infectious Diseases, San Paolo Hospital, University of Milan, Milan, Italy
    J Antimicrob Chemother 58:1086-9. 2006
    ..The correlation between subclinical hypothyroidism [thyroid stimulating hormone (TSH)>4 mIU/L with normal free triiodothyroxine and free thyroxine levels], HIV infection and HAART is still unclear...
  33. ncbi request reprint Potential predictive factors of osteoporosis in HIV-positive subjects
    Alfonso Fausto
    Department of Radiology, Policlinico San Donato, University of Milan, Via Morandi, 30, 20097 San Donato Milanese, Milan, Italy
    Bone 38:893-7. 2006
    ..Traditional risk factors are predictive of osteopenia/osteoporosis also in HIV-subjects; the association with higher HIV-RNA levels can suggest a direct role of HIV itself in the occurrence of bone disease...